Newer strategies for the treatment of heparin-induced thrombocytopenia.
Treatment with heparin is associated with two types of thrombocytopenia. One is a mild, transient, nonimmune disorder, generally without adverse clinical consequence. The other, known as heparin-induced thrombocytopenia (HIT), is a potentially serious, immunoglobulin-mediated reaction with a paradoxic high risk of thromboembolic events. Various treatment options for HIT are discussed, with emphasis on pharmacologic approaches that control the increased thrombin generation characteristic of this disorder.
Warkentin
T E
TE
Department of Laboratory Medicine, Hamilton Health Sciences Corporation, McMaster University, Ontario, Canada.
Barkin
R L
RL
D006493:Heparin / Q000009:adverse effects*; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000188:drug therapy / Q000628:therapy*
D006493:Heparin